# Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

> **NCT01502202** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 162 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Placebo
- **DRUG:** Pemetrexed plusCIsplatin

## Key facts

- **NCT ID:** NCT01502202
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2014-08
- **Final completion:** 2015-02
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2012-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502202, "Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01502202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*